特应性皮炎患者中度普利尤单抗相关结膜炎的危险因素
本病例系列纳入2017年3月14日至2018年3月29日期间在某二级诊疗中心接受度普利尤单抗治疗的142例特应性皮炎患者,其中12例发生结膜炎。所有患者结膜炎发生时特应性皮炎均改善,IGA评分平均下降1.9分,受累体表面积平均下降47.8%。结论认为基线特应性皮炎更严重、对度普利尤单抗反应良好且特应性表型增多的患者更易发生严重结膜炎,可能需要停药。
要点
- 12例患者发生度普利尤单抗相关结膜炎,平均年龄30岁,7例(58%)为男性。
- 结膜炎发生时所有患者特应性皮炎均改善,IGA评分平均下降1.9分,受累体表面积平均下降47.8%。
- 停药患者均在度普利尤单抗初始治疗时患有严重特应性皮炎,且除特应性皮炎外至少合并1种特应性疾病。
核心结论
- 度普利尤单抗治疗特应性皮炎后发生的结膜炎可能严重到需要停止治疗。
- 基线特应性皮炎更严重、对度普利尤单抗反应良好且特应性表型增多的患者更可能发生严重结膜炎。
- 需要研究来确认发生结膜炎的相关危险因素并确定有效的治疗方法。
研究设计与样本
- 病例系列研究,纳入2017年3月14日至2018年3月29日期间在某二级诊疗中心接受度普利尤单抗治疗特应性皮炎的142例患者中报告发生结膜炎的12例患者。
- 患者接受600 mg度普利尤单抗负荷剂量注射,此后每2周注射300 mg。
主要发现
- 12例患者中7例(58%)为男性,结膜炎发生时平均(SD)年龄为30(8.1)岁。
- 所有患者在结膜炎诊断时特应性皮炎均改善,IGA评分平均(SD)下降1.9(0.8)分,受累体表面积平均(SD)下降47.8%(11.2%)。
- 12例患者中9例(75%)基线特应性皮炎严重,IGA评分为4分。
- 所有停药患者在度普利尤单抗初始给药时均患有严重特应性皮炎,且除特应性皮炎外至少合并1种特应性疾病。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Clinical trials of dupilumab for atopic dermatitis (AD) have reported an increased incidence of conjunctivitis in patients who received dupilumab compared with those who received placebo. OBJECTIVE: To describe the characteristics of patients who develop conjunctivitis secondary to dupilumab treatment for AD. DESIGN, SETTING, AND PARTICIPANTS: Case series of 12 patients who reported development of conjunctivitis from a cohort of 142 patients treated with dupilumab for AD at a secondary care center from March 14, 2017, to March 29, 2018. EXPOSURES: Patients received a 600-mg injection of dupilumab as a loading dose and a 300-mg injection every 2 weeks thereafter. MAIN OUTCOMES AND MEASURES: Primary outcome measures were severity of AD as measured by the Investigator Global Assessment (IGA) score, a 5-point scale from 0 (clear) to 4 (severe), at the time of dupilumab initiation and at conjunctivitis onset. RESULTS: Of the 12 patients included in this series, 7 (58%) were male. The mean (SD) age of patients was 30 (8.1) years at the time conjunctivitis developed. All patients showed improvement of their AD at the time of conjunctivitis diagnosis, with a mean (SD) 1.9 (0.8)-point decrease in IGA score and 47.8% (11.2%) decrease in body surface area affected. Nine of the 12 patients (75%) had severe baseline AD with an IGA score of 4. All patients who discontinued treatment had severe AD at the time of initial dupilumab administration and had at least 1 atopic condition in addition to AD. CONCLUSIONS AND RELEVANCE: Conjunctivitis that develops after administration of dupilumab to treat AD may be severe enough to necessitate stopping therapy. Severe conjunctivitis was more likely to develop in patients with more severe baseline AD who had a good response to dupilumab and an increased atopic phenotype. Studies are needed to confirm risk factors associated with development of conjunctivitis and to determine effective treatment.
引用
- Treister AD, Kraff-Cooper C, Lio PA, et al. Risk Factors for Dupilumab-Associated Conjunctivitis in Patients With Atopic Dermatitis. JAMA Dermatol. 2018. PMID: 30167653. doi:10.1001/jamadermatol.2018.2690
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。